◎ Sugi Atlas

Atlas / Drug / Serlopitant

Serlopitant

drug
On this page

Also known as MK-0594Vpd-737

Summary

Serlopitant (CHEMBL447955) is a phase-3 clinical-stage small molecule targeting TACR1; indicated across 2 conditions including epidermolysis bullosa.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • Targets: 1 (TACR1)
  • Indications: 2 conditions
  • Clinical trials: 11
  • Chemistry: 555.5 Da · C29H28F7NO2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL447955
NameSerlopitant
TypeSmall molecule
Max phase3
FDA approvedno
PubChem CID23653789
Molecular formulaC29H28F7NO2
Molecular weight555.5
InChIKeyFLNYCRJBCNNHRH-OIYLJQICSA-N

SMILES: C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2CC[C@@H]3CN(C[C@H]3[C@@H]2C4=CC=C(C=C4)F)C5=CC(=O)CC5

IUPAC name: 3-[(3aR,4R,5S,7aS)-5-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(4-fluorophenyl)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]cyclopent-2-en-1-one

Also known as: MK-0594, Serlopitant, Vpd-737, VPD-737, SERLOPITANT

Patent coverage: 117 distinct patent families (295 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
TACR1NK1 receptorAntagonist10.220.7%P25103

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Substance-K receptor, Substance-P receptor, Cytochrome P450 2D6, Cytochrome P450 2C9, Cytochrome P450 3A4, Cytochrome P450 2C19, Cytochrome P450 2C8, Neuromedin-K receptor.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
TACR110.22IC500.06nMCHEMBL_ACT_13366729
TACR110.22IC500.06nMCHEMBL_ACT_2527016
TACR28.62Ki2.4nMCHEMBL_ACT_2527031
TACR38.62Ki2.4nMCHEMBL_ACT_2527032
TACR18.02IC509.5nMCHEMBL_ACT_13366727
TACR18.02IC509.5nMCHEMBL_ACT_2527024
TACR35.62IC502400nMCHEMBL_ACT_13366723
TACR25.62IC502400nMCHEMBL_ACT_13366725

Target pathways

Aggregated over 1 target gene(s): TACR1.

Top Reactome pathways

4 total, by targets touching each:

PathwayTargetsGenes
Tachykinin receptors bind tachykinins1TACR1
G alpha (q) signalling events1TACR1
Cargo recognition for clathrin-mediated endocytosis1TACR1
Clathrin-mediated endocytosis1TACR1

Dominant GO biological processes

GO termTargets
aggressive behavior1
positive regulation of leukocyte migration1
angiotensin-mediated drinking behavior1
inflammatory response1
adenylate cyclase-activating G protein-coupled receptor signaling pathway1
phospholipase C-activating G protein-coupled receptor signaling pathway1
positive regulation of cytosolic calcium ion concentration1
phospholipase C-activating tachykinin receptor signaling pathway1
tachykinin receptor signaling pathway1
long-term memory1
associative learning1
detection of abiotic stimulus1
response to ozone1
positive regulation of epithelial cell migration1
response to auditory stimulus1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
epidermolysis bullosa2MONDO:0006541EFO:1000690

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

PhaseTrials
PHASE28
PHASE33

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03540160PHASE3TERMINATEDStudy of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
NCT03546816PHASE3COMPLETEDStudy of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
NCT03677401PHASE3COMPLETEDStudy of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
NCT01951274PHASE2COMPLETEDVPD-737 for Treatment of Chronic Pruritus
NCT02196324PHASE2COMPLETEDA Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
NCT02654483PHASE2COMPLETEDNeurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
NCT02975271PHASE2TERMINATEDStudy of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
NCT03282591PHASE2COMPLETEDStudy of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
NCT03343639PHASE2COMPLETEDStudy of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis
NCT03836001PHASE2COMPLETEDA Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa
NCT03841331PHASE2COMPLETEDStudy of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

44 molecules share ≥1 primary target. Top 44 by shared-target count:

MoleculeSourceStatusShared targets
ACLIDINIUM BROMIDEChEMBL + PubChemPhase 4 (approved)TACR1
FIDAXOMICINChEMBL + PubChemPhase 4 (approved)TACR1
ROLAPITANTChEMBL + PubChemPhase 4 (approved)TACR1
AMOXAPINEChEMBLPhase 4 (approved)TACR1
APREPITANTChEMBLPhase 4 (approved)TACR1
ARIPIPRAZOLEChEMBLPhase 4 (approved)TACR1
ASTEMIZOLEChEMBLPhase 4 (approved)TACR1
BOSUTINIBChEMBLPhase 4 (approved)TACR1
CARVEDILOLChEMBLPhase 4 (approved)TACR1
CLOTRIMAZOLEChEMBLPhase 4 (approved)TACR1
CYCLOSPORINEChEMBLPhase 4 (approved)TACR1
DEXTROMETHORPHANChEMBLPhase 4 (approved)TACR1
DOXAZOSINChEMBLPhase 4 (approved)TACR1
ECONAZOLEChEMBLPhase 4 (approved)TACR1
HALOPERIDOLChEMBLPhase 4 (approved)TACR1
ITRACONAZOLEChEMBLPhase 4 (approved)TACR1
LANSOPRAZOLEChEMBLPhase 4 (approved)TACR1
MICONAZOLEChEMBLPhase 4 (approved)TACR1
NEFAZODONEChEMBLPhase 4 (approved)TACR1
NETUPITANTChEMBLPhase 4 (approved)TACR1
NILOTINIBChEMBLPhase 4 (approved)TACR1
PAROXETINEChEMBLPhase 4 (approved)TACR1
RITONAVIRChEMBLPhase 4 (approved)TACR1
TAMOXIFENChEMBLPhase 4 (approved)TACR1
TERFENADINEChEMBLPhase 4 (approved)TACR1
THIOTHIXENEChEMBLPhase 4 (approved)TACR1
TRAZODONEChEMBLPhase 4 (approved)TACR1
CASOPITANTChEMBLPhase 3TACR1
SAREDUTANTChEMBLPhase 3TACR1
BEFETUPITANTChEMBLPhase 2TACR1
DAPITANTChEMBLPhase 2TACR1
DNK333ChEMBLPhase 2TACR1
LANEPITANTChEMBLPhase 2TACR1
ORVEPITANTChEMBLPhase 2TACR1
OSANETANTChEMBLPhase 2TACR1
SPERGUALINChEMBLPhase 2TACR1
TALNETANTChEMBLPhase 2TACR1
TELMAPITANTChEMBLPhase 2TACR1
VESTIPITANTChEMBLPhase 2TACR1
VOFOPITANTChEMBLPhase 2TACR1
AlogliptinPubChemApprovedTACR1
BelzutifanPubChemApprovedTACR1
PropoxyphenePubChemApprovedTACR1
Tiotropium Bromide MonohydratePubChemApprovedTACR1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot